Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- World’s first meningitis B national infant vaccination programme shows 75% drop in cases over three years
- US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
- Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare
Tweets from GSK
-
GSK @GSK
As one of the few major #pharma companies continuing to invest in AMR research, we welcome the AMR Benchmark Report and its findings. Phil Thomson, President, Global Affairs at GSK, shares his view on the need for action to ensure continued progress: gsk.to/37hkxrh #AMR
about 1 day ago
-
GSK @GSK
The AMR Benchmark Report is an important assessment of efforts being made in our industry. It's good the Benchmark recognises our contribution, but more must be done through action from Governments and other stakeholders, as well as the private sector. gsk.to/37gxr8P twitter.com/AtMIndex/statu…
about 1 day ago
-
GSK @GSK
We had a great time at #JPMHC20 this week, talking about our long-term priorities, oncology research and patient-driven science. Go #BehindTheScience to find out more gsk.to/361USS3
about 6 days ago
